Why the study?
Do intravenous streptokinase, oral aspirin, and intravenous heparin reduce mortality, reinfarction, and stroke in patients with suspected acute myocardial infarction?
Do intravenous streptokinase, oral aspirin, and intravenous heparin reduce mortality, reinfarction, and stroke in patients with suspected acute myocardial infarction?
This pilot study demonstrated the potential mortality benefit of aspirin and the stroke reduction benefit of streptokinase in acute myocardial infarction, paving the way for the landmark ISIS-2 trial.
Answers are grounded in this paper and cite their sources.
Supports aspirin and streptokinase in suspected AMI; extends evidence and informs larger confirmatory trials.
619 patients with suspected acute myocardial infarction (MI) were randomized to receive either a high-dose short-term intravenous infusion of streptokinase (1.5 MU over one hour) or placebo. Using a '2 × 2 × 2 factorial' design, patients were also randomized to receive either oral aspirin (325 mg on alternate days for 28 days) or placebo and separately randomized to receive either intravenous heparin (1000 1U h-1 for 48 hours) or no heparin. Streptokinase (SK) was associated with a nonsignificant (NS) increase in non-fatal reinfarc–tion (3.9% SKvs 2.9% placebo) and decrease in mortality (7.5%vs9.7% in hospital plus 6.1%vs 8.7% after discharge). After SK, there were significantly fewer strokes (0.5% vs 2.4%; 2P<0.05), but significantly more minor adverse events (e.g. hypotension and bradycardial, allergies, bruises or minor bleeds, nausea). Aspirin was associated with fewer non-fatal reinfarctions (3.2% aspirin vs 39% placebo; NS), deaths (in hospital: 61% vs 10.5%; 2P<0.05, and after discharge: 7.0% vs 6.9%; NS), and strokes (0.3% vs 2.0%; NS). Heparin was associated with a decrease in reinfarction (2.2% heparin vs 4.9% no heparin; NS), though not in mortality (in hospital: 8.0% vs 8.5%; NS, and after discharge: 7.0% vs 6.9%; NS), and with a trend towards more strokes (1.6% vs 0.7%; NS) and more bruising and bleeding (14% vs 12%; NS). To assess more reliability the effects of aspirin and of this SK regimen on mortality, about 400 hospitals worldwide are now collaborating in a large (about 20 000 patients planned ) randomized trial ( ISIS-2). for which the present study was a pilot.
No takes yet. Share an insight, caveat, or question.
ISIS PILOT STUDY INVESTIGATION (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: